The pharmacokinetic, pharmacodynamic and pharmacogenomic outcomes of reduced dosage of efavirenz: the Encore1 study

Website
http://purl.org/au-research/grants/nhmrc/1048402

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.

Funded Activity Summary

Our primary aim is to assess blood concentrations of a drug called efavirenz, an important drug used in the treatment of HIV infection and associate these with variability of genes that control metabolism of the drug. A better understanding of gene variability and how it relates to safety and efficacy outcomes at a reduced, compared to a standard dose of efavirenz could support improved treatment of HIV disease.

Funded Activity Details

Start Date: 2013

End Date: 2015

Funding Scheme: Project Grants

Funding Amount: $1,234,943.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Infectious Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Related Researchers

No related researchers have been discovered for grant The pharmacokinetic, pharmacodynamic and pharmacogenomic outcomes of reduced dosage of efavirenz: the Encore1 study.

Related Organisations

No related organisations have been discovered for grant The pharmacokinetic, pharmacodynamic and pharmacogenomic outcomes of reduced dosage of efavirenz: the Encore1 study.